Fisher & Paykel Healthcare Too Pricey?

Australia | Nov 29 2019

Fisher & Paykel Healthcare experienced a jump in device sales during the first half but brokers remain concerned about the high price of the stock.

-Will new mask quality/features be enough to drive an improvement in US market share
-Decline in gross profit margins of around -50 basis points expected in FY20
-Launch of Vitera in the US a key catalyst for mask growth in 2020


By Eva Brocklehurst

Nasal high-flow therapy performed strongly for Fisher & Paykel Healthcare ((FPH)) in the first half of FY20. The company has lifted FY20 expectations for a third time this year, Wilsons notes, albeit for low-quality reasons such as FX and R&D grants.

Full-year guidance is for operating revenue of NZ$1.19bn and net profit of NZ$255-265m, which Credit Suisse assesses has absorbed a modest adverse impact from a higher assumed NZD/USD rate.

Macquarie believes the results provide a platform for the company's revenue outlook over the medium term but notes valuation multiples are priced ahead of Australasian healthcare peers, and elevated versus historical levels.

Moreover, risks remain significant and temper the view. The broker awaits feedback from the US market and new releases in early 2020, noting this is a high-quality business and the market is capitalising market-leading growth opportunities across both hospital and homecare.

UBS agrees that the stock is trading well above global peers on an EPS (earnings per share) growth-adjusted basis. New applications for consumables were robust in the first half, with a growth rate of 23% on a constant currency basis.

A jump in device sales was underpinned by tenders, which is a reflection of the company's dominance of humidification, UBS asserts, and less about large Airvo orders for OptiFlow use outside of the intensive care unit.

Wilsons finds a couple of characteristics of the business at odds with the valuation. The sleep business within the Homecare division faces structural challenges, given competitor activity ahead of a new round of US reimbursement reform. The broker is also not convinced the new mask quality/features are enough to drive an improvement in market share in the US.

The company still expects a decline in gross profit margins of -50 basis points in FY20 on the back of additional depreciation and start-up costs, associated with the commissioning of the second manufacturing facility in Mexico.

Macquarie was expecting a more pronounced impact on margins in the first half and suspects margins will remain relatively static over FY20. Headwinds to margins include the start-up of the Auckland manufacturing facilities in FY21. Management has highlighted an additional $20m in capital expenditure as it improves capacity in both Mexico and New Zealand.

The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE

If you already had your free trial, why not join as a paying subscriber? CLICK HERE